PHILADELPHIA--(BUSINESS WIRE)--July 27, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News) today announced that it has resolved its outstanding regulatory issues with the American Stock Exchange (AMEX). In a letter dated July 5, 2006, Hemispherx Biopharma, a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for the treatment of viral and immune-based disorders, was informed that after duly filing Form 10-K with the Securities and Exchange Commission for the year ended December 31, 2005 and the Form 10Q for the quarter ended March 31, 2006, it is now in full compliance. The company had missed the deadline for filing Form 10-K for the fiscal year ended December 31, 2005, violating AMEX guidelines.
